The case of the HIV drug price scandal in America and the media as an enabler for social justice

6127242068_23c80ef94f_b

By Jonathan Theuring

On the night of Tuesday 22nd September I went to bed appalled and incensed by thoughts of Martin Shkreli, a hedge fund manager and executive chairman of Turing Pharmaceuticals. He recently increased the price of a life-saving drug, trade name Daraprim, used in the treatment of HIV patients after having achieved ‘manufacturing exclusivity’ by purchasing the rights to its production.

The following morning I awoke to the breaking news that, under the immense weight of mounting social pressure from the media, politicians (Hillary Clinton included), and medical groups, Shkreli announced that his company would rollback the price of the drug in order to make it more affordable for the many people who urgently require it.

Two things struck me about this incident. On the one hand, I felt that it showcased the depravity of leading figures in the US pharmaceuticals industry and the injustice that stems from the lack of appropriate governmental legislation therein. On the other, it prompted me to muse on the lightning-fast reactions of the modern media and the kind of safeguarding role it has come to play within society.

I agree that we are right to criticise the media when it contributes to certain societal issues such as eating disorders through the pressure it places on individuals. And yet all too often we forget that without the presence of the major tabloids, Shkreli might not have been coerced into slashing the price of Daraprim. For me, the pace with which Shkreli was forced to respond – quite literally overnight – was astounding and a testament to the remarkable beneficial influence the media can have.

In the Daraprim case, no exact revised figure for the cost of the drug has thus far been declared despite Turing Pharmaceuticals’ vow to carry this out and I await the announcement eagerly. Never usually too shy of the spotlight, a smarmy Shkreli spoke out ominously in the press the other day about how the reduction in the price of Daraprim could force him to axe research into “lethal diseases” and fire staff, having a disastrous knock-on effect on the pharmaceuticals industry overall.

This is not the first time Shkreli has been involved in murky corporate dealings in the pharmaceuticals trade: The Independent reported that the Pharma CEO had orchestrated similar price-fixing attacks within the industry on a previous occasion, this time relating to a drug designed for children with an ‘incurable kidney disease’. It really is no wonder that Shkreli has in recent times been hailed ‘the most hated man in America’. Last month the executive chairman was once more dragged into public disrepute as a result of a $65 million lawsuit that was filed against him by Retrophin, a biopharmaceuticals company he himself founded back in 2011, only to have his contract terminated in October 2014.

Shkreli – and devil’s advocates on the comments sections of newspapers across the land, for that matter – have been swift to point out that, in terms of its US circulation, the drug is only prescribed to around 2,000 people per year. For the select few for whom Daraprim is the most appropriate course of medical action, however, the treatment is by no means short-term; without insurance the 5,000% price hike would have meant that a course, delivered over several years, could amount to several hundred thousand dollars (depending on the severity and onset stage of the individual’s condition).

I would argue that the principal ought to remain the same regardless of the amount of people involved. To control the supply of a life-saving drug simply to meet the needs of a purely profit-driven company is morally wrong in every sense. Moreover, the fact that such a small sector of society requires Daraprim as part of their treatment suggests that Turing Pharmaceuticals specifically selected this drug on the basis that they would encounter few difficulties in monopolising the market. The Daraprim case, then, exemplifies the kind of positive impact the press can have in protecting small minority groups from self-serving, predatory corporations.

We complain daily about the sensationalist click-bait articles produced in this copy/paste era of Reddit and i100, and yet the global community we have come to know as ‘the media’ operates also as a species of safety net. Within a democratic society we are actively encouraged to seize our rights to freedoms of speech and thought through mediums like writing, whether it be for a newspaper or a personal blog, and by doing so we assist in the process of flagging up instances like the Shkreli case, ultimately contributing to the mechanisms of social justice.

Image: Images Money (TaxRebate.org.uk) via Flickr